Home / Investors / Strategy

Strategy

Strengthen our positioning as a specialist further developing new immunodiagnostics and molecular diagnostics products leveraging on the complete offer of automated proprietary analyzers on both technologies.

Immunodiagnostics
Molecular diagnostics

Consolidate the leading positioning in the immunodiagnostics leveraging the breadth of our CLIA product portfolio and further develop new specialty tests.

USA

 StrategyRelated business
development activity

Commercial clients base

  • Consolidation of the positioning through me-too tests and the expansion of CLIA specialty tests’ offer

Beckman Coulter

Qiagen

Hospitals Networks

  • Penetration of the Hospitals segment (Hospital Network), leveraging on specialty tests and me too tests (target: 1,100 hospitals)


LIAISON XS

Qiagen

 

Physician Office Labs

  • Penetration of the Physician Office Labs’ segment, leveraging on the LIAISON XS, with launch scheduled in 2020

LIAISON XS

Qiagen

 Me too tests
Specialties tests

Europe

 StrategyRelated business
development activity

Large Labs

  • Continue reinforce strategic alliances and explore new commercial opportunities
  • Consolidation of the positioning through me-too tests and the expansion of CLIA specialty tests’ offer 


Siemens

Qiagen

Mid Labs

  • Expand LIAISON XL base and add on opportunities leveraging on menu differentiation
  • Continuation of the tests’ conversion process from ELISA to CLIA technology
  • Consolidation of the positioning through me-too tests and the expansion of CLIA specialty tests’ offer 

Siemens

Qiagen

Small Labs

  • Support decentralization process  through the combined offer of LIAISON XL e XS platforms (Hub and Spoke strategy)
  • Continuation of the tests’ conversion process from ELISA to CLIA technology supported by the introduction of the LIAISON XS platform

Siemens

Qiagen

LIAISON XS

 Me too tests
 Specialties tests

China

 StrategyRelated business
development activity

Class III Hospitals

  • Consolidation of the positioning through me-too tests and the expansion of CLIA specialty tests’ offer 
  • Lauch of latent tuberculosis test in partnership with QIAGEN planned in 2020
  • Conversion of tests from ELISA to CLIA technology

Qiagen

Beckman Coulter

Class II Hospitals

  • Consolidation of the positioning through me-too tests and the expansion of CLIA specialty tests’ offer 
  • Lauch of latent tuberculosis test in partnership with QIAGEN planned in 2021

Qiagen

China Manifacturing

  • In the timeframe 2019-2022 DiaSorin plans to set up a new manufacturing site in joint venture with a recognized Chinese academic institution, whose focus is manufacturing high quality CLIA tests for the local market
 
 Me too tests
 Specialties tests

New products launches to enlarge the menu adding to the LIAISON MDX platform (currently used to serve central hospital laboratories) a new Point of Care molecular platform.


 Strategy 



Expand offer with 5/6 new tests yearly:

  • Kits (Universal Disc)
  • ASRs (Direct amplification disc)